Ciprofol Ameliorates Myocardial Ischemia/Reperfusion Injury by Inhibiting Ferroptosis Through Upregulating HIF-1α

Overview

Journal Drug Des Devel Ther

Specialty Pharmacology

Date 2024 Dec 23

PMID 39711877

Authors

Jun Ding

Bi-Ying Wang

Yu-Fan Yang

Ling-Yu Kuai

Jing-Jie Wan

Mian Zhang

Hai-Yan Xia

Yao Wang

Zhong Zheng

Xiao-Wen Meng

Ke Peng

Fu-Hai Ji

Affiliations

Soon will be listed here.

Abstract

Purpose: Ciprofol is a novel intravenous anesthetic that has been increasingly used in clinical anesthesia and sedation. Studies suggested that ciprofol reduced oxidative stress and inflammatory responses to alleviate cerebral ischemia/reperfusion (I/R) injury, but whether ciprofol protects the heart against I/R injury and the mechanisms are unknown. Herein, we assessed the effects of ciprofol on ferroptosis during myocardial I/R injury.

Methods: Experimental models of myocardial I/R injury in mice (ischemia for 30 min and reperfusion for 24 h) and hypoxia/reoxygenation (H/R) injury in H9c2 cardiomyocytes (hypoxia for 6 h followed by 6 h of reoxygenation) were established. Ciprofol was used prior to ischemia or hypoxia. Echocardiography, myocardial TTC staining, HE staining, DAB-enhanced Perl's staining, transmission electron microscopy, FerroOrange staining, Liperfluo staining, JC-1 staining, Rhodamine-123 staining, DCFH-DA staining, and Western blot were performed. Cell viability, serum cardiac enzymes, and oxidative- and ferroptosis-related biomarkers were measured. HIF-1α siRNA transfection and the specific inhibitor BAY87-2243 were utilized for mechanistic investigation.

Results: Ciprofol treatment reduced myocardial infarct area and myocardium damage, alleviated oxidative stress and mitochondrial injury, suppressed Fe accumulation and ferroptosis, and improved cardiac function in mice with myocardial I/R injury. Ciprofol also increased cell viability, attenuated mitochondrial damage, and reduced intracellular Fe and lipid peroxidation in cardiomyocytes with H/R injury. Ciprofol enhanced the protein expression of HIF-1α and GPX4 and reduced the expression of ACSL4. Specifically, the protective effects of ciprofol against I/R or H/R injury were abolished by downregulating the expression of HIF-1α using siRNA transfection or the inhibitor BAY87-2243.

Conclusion: Ciprofol ameliorated myocardial I/R injury in mice and H/R injury in cardiomyocytes by inhibiting ferroptosis via the upregulation of HIF-1α expression.

References

Wang Y, Zhang M, Bi R, Su Y, Quan F, Lin Y . ACSL4 deficiency confers protection against ferroptosis-mediated acute kidney injury. Redox Biol. 2022; 51:102262. PMC: 8857079. DOI: 10.1016/j.redox.2022.102262. View

Yang Y, Xia Z, Xu C, Zhai C, Yu X, Li S . Ciprofol attenuates the isoproterenol-induced oxidative damage, inflammatory response and cardiomyocyte apoptosis. Front Pharmacol. 2022; 13:1037151. PMC: 9723392. DOI: 10.3389/fphar.2022.1037151. View

Liang P, Dai M, Wang X, Wang D, Yang M, Lin X . Efficacy and safety of ciprofol vs. propofol for the induction and maintenance of general anaesthesia: A multicentre, single-blind, randomised, parallel-group, phase 3 clinical trial. Eur J Anaesthesiol. 2023; 40(6):399-406. PMC: 10155686. DOI: 10.1097/EJA.0000000000001799. View

Liu L, Wang K, Yang Y, Hu M, Chen M, Liu X . Population pharmacokinetic/pharmacodynamic modeling and exposure-response analysis of ciprofol in the induction and maintenance of general anesthesia in patients undergoing elective surgery: A prospective dose optimization study. J Clin Anesth. 2023; 92:111317. DOI: 10.1016/j.jclinane.2023.111317. View

Cai W, Liu L, Shi X, Liu Y, Wang J, Fang X . Alox15/15-HpETE Aggravates Myocardial Ischemia-Reperfusion Injury by Promoting Cardiomyocyte Ferroptosis. Circulation. 2023; 147(19):1444-1460. DOI: 10.1161/CIRCULATIONAHA.122.060257. View

Hernandez-Resendiz S, Prakash A, Loo S, Semenzato M, Chinda K, Crespo-Avilan G . Targeting mitochondrial shape: at the heart of cardioprotection. Basic Res Cardiol. 2023; 118(1):49. PMC: 10643419. DOI: 10.1007/s00395-023-01019-9. View

Alexander T, Kumbhani D, Mullasari Sankardas A . The Future of Pharmacoinvasive Therapy for ST-Segment-Elevation Myocardial Infarction Reperfusion in the Post-STREAM Era. Circulation. 2024; 149(10):732-733. DOI: 10.1161/CIRCULATIONAHA.123.066703. View

Yan J, Li Z, Liang Y, Yang C, Ou W, Mo H . Fucoxanthin alleviated myocardial ischemia and reperfusion injury through inhibition of ferroptosis the NRF2 signaling pathway. Food Funct. 2023; 14(22):10052-10068. DOI: 10.1039/d3fo02633g. View

Lei X, Teng W, Fan Y, Zhu Y, Yao L, Li Y . The protective effects of HIF-1α activation on sepsis induced intestinal mucosal barrier injury in rats model of sepsis. PLoS One. 2022; 17(5):e0268445. PMC: 9109928. DOI: 10.1371/journal.pone.0268445. View

10.

Sun X, Zhang M, Zhang H, Fei X, Bai G, Li C . Efficacy and safety of ciprofol for long-term sedation in patients receiving mechanical ventilation in ICUs: a prospective, single-center, double-blind, randomized controlled protocol. Front Pharmacol. 2023; 14:1235709. PMC: 10475522. DOI: 10.3389/fphar.2023.1235709. View

11.

Wu X, Li Y, Zhang S, Zhou X . Ferroptosis as a novel therapeutic target for cardiovascular disease. Theranostics. 2021; 11(7):3052-3059. PMC: 7847684. DOI: 10.7150/thno.54113. View

12.

Li S, Lei Z, Yang X, Zhao M, Hou Y, Wang D . Propofol Protects Myocardium From Ischemia/Reperfusion Injury by Inhibiting Ferroptosis Through the AKT/p53 Signaling Pathway. Front Pharmacol. 2022; 13:841410. PMC: 8966655. DOI: 10.3389/fphar.2022.841410. View

13.

Kekupaa Knutson A, Williams A, Boisvert W, Shohet R . HIF in the heart: development, metabolism, ischemia, and atherosclerosis. J Clin Invest. 2021; 131(17). PMC: 8409592. DOI: 10.1172/JCI137557. View

14.

Liu S, Bi Y, Han T, Li Y, Wang Q, Wu N . The E3 ubiquitin ligase MARCH2 protects against myocardial ischemia-reperfusion injury through inhibiting pyroptosis via negative regulation of PGAM5/MAVS/NLRP3 axis. Cell Discov. 2024; 10(1):24. PMC: 10897310. DOI: 10.1038/s41421-023-00622-3. View

15.

Ding Y, Long Y, Yang H, Zhuang K, Ji F, Peng K . Efficacy and safety of ciprofol for general anaesthesia induction in elderly patients undergoing major noncardiac surgery: A randomised controlled pilot trial. Eur J Anaesthesiol. 2022; 39(12):960-963. DOI: 10.1097/EJA.0000000000001759. View

16.

Du J, Wang C, Chen Y, Zhong L, Liu X, Xue L . Targeted downregulation of HIF-1α for restraining circulating tumor microemboli mediated metastasis. J Control Release. 2022; 343:457-468. DOI: 10.1016/j.jconrel.2022.01.051. View

17.

Marijon E, Narayanan K, Smith K, Barra S, Basso C, Blom M . The Lancet Commission to reduce the global burden of sudden cardiac death: a call for multidisciplinary action. Lancet. 2023; 402(10405):883-936. DOI: 10.1016/S0140-6736(23)00875-9. View

18.

Qin L, Ren L, Wan S, Liu G, Luo X, Liu Z . Design, Synthesis, and Evaluation of Novel 2,6-Disubstituted Phenol Derivatives as General Anesthetics. J Med Chem. 2017; 60(9):3606-3617. DOI: 10.1021/acs.jmedchem.7b00254. View

19.

Qian W, Liu D, Han Y, Liu M, Liu B, Ji Q . Cyclosporine A-loaded apoferritin alleviates myocardial ischemia-reperfusion injury by simultaneously blocking ferroptosis and apoptosis of cardiomyocytes. Acta Biomater. 2023; 160:265-280. DOI: 10.1016/j.actbio.2023.02.025. View

20.

Chen L, Xie Y, Du X, Qin W, Huang L, Dai J . The Effect of Different Doses of Ciprofol in Patients with Painless Gastrointestinal Endoscopy. Drug Des Devel Ther. 2023; 17:1733-1740. PMC: 10275323. DOI: 10.2147/DDDT.S414166. View